ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

Kouji Kajinami, Margaret E. Brousseau, Chorthip Nartsupha, José M. Ordovás, Ernst J. Schaefer

Journal of Lipid Research · 2004 · 94 citations · 24 references

DOIFull text

Open access

Concepts

Abstract

The mechanisms responsible for interindividual variation in response to statin therapy remain uncertain. It has been shown that hepatic cholesterol synthesis is associated with ATP binding cassette transporter G5 and G8 (ABCG5/8) activities. To test the hypothesis that genetic variation in ABCG5/8 might influence the plasma lipid response to statin therapy, we examined five nonsynonymous polymorphisms at the ABCG5/8 loci (Q604E, D19H, Y54C, T400K, and A632V) in 338 hypercholesterolemic patients treated with 10 mg atorvastatin. In carriers of the D19H variant, means of posttreatment values and adjusted percent reductions in LDL cholesterol (LDLC) were significantly lower (P = 0.028) and greater (P = 0.036) (112 mg/dl, 39.7%) than those of noncarriers (119 mg/dl, 36.2%), respectively, while no significant difference was observed in percent reductions in total cholesterol. Stepwise multiple regression analysis revealed significant and independent associations with absolute or percent reduction between D19H genotype and posttreatment LDL cholesterol levels. The other polymorphisms were not significantly associated with treatment effects.These results suggest that, in patients with hypercholesterolemia, the ABCG8 D19H variant is associated with greater LDLC-lowering response to atorvastatin therapy. The mechanisms responsible for interindividual variation in response to statin therapy remain uncertain. It has been shown that hepatic cholesterol synthesis is associated with ATP binding cassette transporter G5 and G8 (ABCG5/8) activities. To test the hypothesis that genetic variation in ABCG5/8 might influence the plasma lipid response to statin therapy, we examined five nonsynonymous polymorphisms at the ABCG5/8 loci (Q604E, D19H, Y54C, T400K, and A632V) in 338 hypercholesterolemic patients treated with 10 mg atorvastatin. In carriers of the D19H variant, means of posttreatment values and adjusted percent reductions in LDL cholesterol (LDLC) were significantly lower (P = 0.028) and greater (P = 0.036) (112 mg/dl, 39.7%) than those of noncarriers (119 mg/dl, 36.2%), respectively, while no significant difference was observed in percent reductions in total cholesterol. Stepwise multiple regression analysis revealed significant and independent associations with absolute or percent reduction between D19H genotype and posttreatment LDL cholesterol levels. The other polymorphisms were not significantly associated with treatment effects. These results suggest that, in patients with hypercholesterolemia, the ABCG8 D19H variant is associated with greater LDLC-lowering response to atorvastatin therapy. HMG-CoA reductase inhibitors, statins (1Endo A. The discovery and development of HMG-CoA reductase inhibitors.J. Lipid Res. 1992; 33: 1569-1582Abstract Full Text PDF PubMed Google Scholar), are effective in the primary (2Shepherd J. Cobbe S.M. Ford I. Isles C.G. Lorimer A.R. MacFarlane P.W. McKillop J.H. Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.N. Engl. J. Med. 1995; 333: 1301-1307Crossref PubMed Scopus (7459) Google Scholar, 3Downs J.R. Clearfield M. Weis S. Whitney E. Shapiro D.R. Beere P.A. Langendorfer A. Stein E.A. Kruyer W. Gotto Jr., A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA. 1998; 279: 1615-1622Crossref PubMed Scopus (4985) Google Scholar) and secondary (4Scandinavian Simvastatin Survival Study Writing Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389PubMed Google Scholar, 5Sacks F.M. Pfeffer M.A. Moye L.A. Rouleau J.L. Rutherford J.D. Cole T.G. Brown L. Warnica J.W. Arnold J.M. Wun C.C. Davis B.R. Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators.N. Engl. J. Med. 1996; 335: 1001-1009Crossref PubMed Scopus (7185) Google Scholar, 6The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N. Engl. J. Med. 1998; 339: 1349-1357Crossref PubMed Scopus (5557) Google Scholar, 7Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002; 360: 7-22Abstract Full Text Full Text PDF PubMed Scopus (7617) Google Scholar, 8Shepherd J. Blauw G.J. Murphy M.B. Bollen E.L. Buckley B.M. Cobbe S.M. Ford I. Gaw A. Hyland M. Jukema J.W. Kamper A.M. Macfarlane P.W. Meinders A.E. Norrie J. Packard C.J. Perry I.J. Stott D.J. Sweeney B.J. Twomey C. Westendorp R.G. on behalf of the PROSPER study group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.Lancet. 2002; 360: 1623-1630Abstract Full Text Full Text PDF PubMed Scopus (2969) Google Scholar) prevention of coronary artery disease. Statins competitively inhibit cholesterol biosynthesis, thereby decreasing intracellular cholesterol content. In hepatocytes, the reduction in cholesterol content, in turn, causes a decrease in the secretion of apolipoprotein B (apoB)-containing lipoproteins and an upregulation of LDL receptor activity, both of which contribute to the reduction in plasma LDL cholesterol (LDLC) levels observed with statin therapy. ATP binding cassette transporters G5 and G8 (ABCG5/8) are unique proteins located in the plasma membrane, as well as in the intracellular membranes of enterocytes and hepatocytes. Mutations in the genes encoding for ABCG5/8 have been identified as the cause of sitosterolemia (9Berge K.E. Tian H. Graf G.A. Yu L. Grishin N.V. Schultz J. Kwiterovich P. Shan B. Barnes R. Hobbs H.H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.Science. 2000; 290: 1771-1775Crossref PubMed Scopus (1342) Google Scholar, 10Lee M.H. Lu K. Hazard S. Yu H. Shulenin S. Hidaka H. Kojima H. Allikmets R. Sakuma N. Pegoraro R. Srivastava A. Salen G. Dean M. Patel S.B. Idenfitication of a gene, ABCG5, important in the regulation of dietary cholesterol absorption.Nat. Genet. 2001; 27: 79-83Crossref PubMed Scopus (589) Google Scholar, 11Hubacek J.A. Berge K.E. Cohen J.C. Hobbs H.H. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia.Hum. Mutat. 2001; 18: 359-360Crossref PubMed Scopus (143) Google Scholar), a rare inborn error of metabolism characterized by elevated plasma levels of plant sterols due to hyperabsorption and decreased biliary sterol secretion. Impairment of these pathways results in a decrease of cholesterol biosynthesis in hepatocytes (12Bhattacharyya A.K. Connor W.E. Lin D.S. McMurry M.M. Shulman R.S. Sluggish sitosterol turnover and hepatic failure to excrete sitosterol into bile cause expansion of body pool of sitosterol in patients with sitosterolemia and xanthomatosis.Arterioscler. Thromb. 1991; 11: 1287-1294Crossref PubMed Google Scholar, 13Yu L. Hammer R.E. Hawkins J.L. von Bergmann K. Lutjohann D. Cohen J.C. Hobbs H.H. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion.Proc. Natl. Acad. Sci. USA. 2002; 99: 16237-16242Crossref PubMed Scopus (603) Google Scholar), raising the possibility that interindividual variation in plasma cholesterol concentrations (14Weggemans R.M. Zock P.L. Tai E.S. Ordovas J.M. Molhuizen H.O. Katan M.B. ATP binding cassette G5 C1950G polymorphisms may affect blood cholesterol concentrations in humans.Clin. Genet. 2002; 62: 226-229Crossref PubMed Scopus (55) Google Scholar, 15Berge K.E. von Bergmann K. Lutjohann D. Guerra R. Grundy S.M. Hobbs H.H. Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.J. Lipid Res. 2002; 43: 486-494Abstract Full Text Full Text PDF PubMed Google Scholar), and possibly the response to statin treatment, is, in part, due to variation in the ABCG5/8 genes. We, and others, have previously shown that apoE genotype is associated with the plasma lipid response to statin therapy (16Ordovas J.M. Lopez-Miranda F. Perez-Jimenez C. Rodriguez J.S. Park T. Cole T. Schaefer E.J. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.Atherosclerosis. 1995; 113: 157-166Abstract Full Text PDF PubMed Scopus (151) Google Scholar, 17Pedro-Botet J. Schaefer E.J. Bakker-Arkema R.G. Black D.M. Stain E.M. Corella D. Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Atherosclerosis. 2001; 158: 183-193Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar). The present study was undertaken to test the hypothesis that polymorphisms at the ABCG5/8 gene loci are associated with plasma lipid response to statin treatment. Study subjects were the same patient group, in which we found the gender-specific effects of apoE genotype on plasma lipid response to atorvastatin therapy (17Pedro-Botet J. Schaefer E.J. Bakker-Arkema R.G. Black D.M. Stain E.M. Corella D. Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Atherosclerosis. 2001; 158: 183-193Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar, 18Davidson M. McKenney J. Stein E. Schrott H.G. Fayyad R. Black D. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia.Am. J. Cardiol. 1997; 79: 1475-1481Abstract Full Text Full Text PDF PubMed Scopus (225) Google Scholar). Patients were recruited from 31 community- and university-based research centers in the USA. Identical protocols were reviewed and approved by an institutional review board at each site, and written informed consent was obtained prior to the entry of the study from each participant. Men and women with primary hypercholesterolemia, 18–80 years old, with a body mass index (BMI) ≤32 kg/m2 were screened, and all patients began the NCEP step 1 diet during baseline and followed it throughout the study (18Davidson M. McKenney J. Stein E. Schrott H.G. Fayyad R. Black D. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia.Am. J. Cardiol. 1997; 79: 1475-1481Abstract Full Text Full Text PDF PubMed Scopus (225) Google Scholar). Fasting plasma lipoprotein level entry criteria were LDLC values ≥160 mg/dl at week 4 and >145 mg/dl at week 2, with the lower value being within 20% of the higher value, and triglyceride (TG) <400 mg/dl. Patients with impaired hepatic or renal function, diabetes mellitus type I, or uncontrolled diabetes mellitus type II were excluded. Additional exclusion criteria included all unstable medical conditions that might interfere with the evaluation and <80% compliance with study medication during the placebo baseline phase. Patients with elevated plasma aspartate aminotransferase or alanine aminotransferase values >1.5× the upper limit of normal, creatine phosphokinase >3× the upper limit of normal, or unexplained elevations in creatine phosphokinase during the placebo baseline phase were excluded. Patients were excluded if they were taking: any immunosuppressive agent; drugs known to affect lipid levels, possibly interact with study medications, or possibly affect clinical laboratory parameters; and drugs known to be associated with rhabdomyolysis in combination with statins (e.g., cyclosporine and erythromycin); or other lipid-regulating drugs. Patients currently taking a lipid-altering drug could be screened after a 4-week washout period, except for probucol, which required at least 6 months for washout. At the start of the double-blind treatment phase, qualified patients were randomized to one of four parallel treatment groups with once-daily dosing: atorvastatin (10 mg) or lovastatin (20 mg) for 52 weeks, placebo for 16 weeks, and then atorvastatin or lovastatin for 36 weeks. The ABCG5/8 genotypes were determined in 338 subjects from the atorvastatin (10 mg per day) arm of the study. The mean (±SD) age was 58 ± 11 years and BMI 27.0 ± 3.0 kg/m2. Two hundred and three were males (mean age 56 ± 11 years, BMI 27.3 ± 2.7 kg/m2) and 135 females (mean age 61 ± 11 years, BMI 26.5 ± 3.3 kg/m2). Plasma lipid responses were calculated based on both baseline values on placebo and after the 52-week treatment for each subject. Laboratory methods for lipid and lipoprotein measurements, as well as those for DNA analyses, were also described elsewhere (17Pedro-Botet J. Schaefer E.J. Bakker-Arkema R.G. Black D.M. Stain E.M. Corella D. Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Atherosclerosis. 2001; 158: 183-193Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar). In the present study, five prevalent DNA polymorphisms, one in ABCG5 (Q604E) and four in ABCG8 (D19H, Y54C, T400K, and A632V), were studied using a PCR-restriction length polymorphism method. For the D19H polymorphism, a 131 bp fragment, including a G to C substitution site at codon 19 of the ABCG8 gene, was amplified using an oligonucleotide primer set (5′-GCTGGGTCTAAGAGAGCTGC-3′ and 5′-CTTCCCATTGCTCACTCACC-3′) with 35 cycles of amplification (95°C for 30 s, 60°C for 30 s, and 72°C for 30 s). PCR products were digested with 10 units of BstNI (New England BioLabs, Inc., MA), and fragments were separated by 3% agarose gel electrophoresis and visualized by UV after ethidium bromide staining. The remaining four polymorphisms were examined, as described in previous reports (11Hubacek J.A. Berge K.E. Cohen J.C. Hobbs H.H. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia.Hum. Mutat. 2001; 18: 359-360Crossref PubMed Scopus (143) Google Scholar, 15Berge K.E. von Bergmann K. Lutjohann D. Guerra R. Grundy S.M. Hobbs H.H. Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.J. Lipid Res. 2002; 43: 486-494Abstract Full Text Full Text PDF PubMed Google Scholar). All statistical analyses were carried out using the SPSS version 11.0.1. A logarithmic transformation was applied to plasma TG before analysis because of its skewed distribution. To test the effects of genotype on the variables with minimal risk for false positive association, we made comparisons by two stages. First, one-way ANOVA (ANOVA) was applied to evaluate the difference across three genotypes with post hoc Bonferroni correction for multiple subjects carried one or two were with those were for the by for In multiple regression analysis to independent and gender was 1 and 2, and and subjects at least one variant were 1 and 2, was using the the of for were calculated as described elsewhere K.E. von Bergmann K. Lutjohann D. Guerra R. Grundy S.M. Hobbs H.H. Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.J. Lipid Res. 2002; 43: 486-494Abstract Full Text Full Text PDF PubMed Google Scholar). All are as mean ± and all values are based on of variant variant in each polymorphism were as R.M. Zock P.L. Tai E.S. Ordovas J.M. Molhuizen H.O. Katan M.B. ATP binding cassette G5 C1950G polymorphisms may affect blood cholesterol concentrations in humans.Clin. Genet. 2002; 62: 226-229Crossref PubMed Scopus (55) Google Scholar), D19H A. The discovery and development of HMG-CoA reductase inhibitors.J. Lipid Res. 1992; 33: 1569-1582Abstract Full Text PDF PubMed Google Scholar), A.K. Connor W.E. Lin D.S. McMurry M.M. Shulman R.S. Sluggish sitosterol turnover and hepatic failure to excrete sitosterol into bile cause expansion of body pool of sitosterol in patients with sitosterolemia and xanthomatosis.Arterioscler. Thromb. 1991; 11: 1287-1294Crossref PubMed Google Scholar), and 17Pedro-Botet J. Schaefer E.J. Bakker-Arkema R.G. Black D.M. Stain E.M. Corella D. Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Atherosclerosis. 2001; 158: 183-193Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar). All were with the were D19H and were by combination of five examined polymorphisms not The three were observed in the same as previously K.E. von Bergmann K. Lutjohann D. Guerra R. Grundy S.M. Hobbs H.H. Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.J. Lipid Res. 2002; 43: 486-494Abstract Full Text Full Text PDF PubMed Google Scholar), and their were and was found in out of 10 of five = and the five examined polymorphisms, the D19H variant was significantly associated with and lipid levels. LDLC values of subjects at least one variant were significantly lower than those of In percent reductions of LDLC in carriers of D19H variant were significantly greater than that of noncarriers after for age and LDLC levels, both of which are as for statin response The difference was also significant LDLC levels were adjusted not In no significant difference was observed in percent reductions of total cholesterol. To independent variables associated with atorvastatin we multiple regression including lipid levels and cholesterol and each genotype as independent variables analysis revealed that D19H in to age and was significantly and associated with posttreatment LDLC D19H genotype was also associated significantly and with the absolute and percent reduction of LDLC not of the remaining polymorphisms were significantly associated with treatment effects not and lipoprotein concentrations before and after atorvastatin treatment to D19H polymorphism of ABCG8 and were because was found in one and TG levels at baseline were and levels after treatment were and and the percent were and Two of were an and and a results of the were of 58 ± 11 58 ± 11 56 ± 27.0 ± 3.0 27.0 ± 3.0 ± ± ± ± ± ± ± ± 11 ± 11 ± ± ± ± ± ± ± ± 19 ± 19 ± ± ± ± ± 58 ± ± ± mean values of percent were adjusted for age and values of each and were shown with except for the values of all ± mean values of percent were adjusted for age and values of each and were shown with except for the values of all ± mean values of percent were adjusted for age and values of each and were shown with except for the values of all ± mean values of percent were adjusted for age and values of each and were shown with except for the values of all ATP binding cassette transporter body mass total LDL All are as mean ± and were because was found in one and TG levels at baseline were and levels after treatment were and and the percent were and Two of were an and and a results of the were The mean values of percent were adjusted for age and values of each and were shown with except for the values of all in a multiple regression and adjusted values for the posttreatment LDLC level by multiple regression analysis was using variables and D19H gender and for of D19H polymorphism were and gender and subjects variant of D19H polymorphism were 2, Stepwise multiple regression analysis was using variables and D19H gender and for of D19H polymorphism were and gender and subjects variant of D19H polymorphism were 2, in a ATP binding cassette transporter body mass total LDL All are as mean ± The results of study that the ABCG8 D19H variant is significantly and associated with a greater response to while of the remaining polymorphisms was associated with the results are with a genetic association, than a based on the First, in patients with sitosterolemia and suggest that of ABCG5/8 significantly cholesterol synthesis in hepatocytes (12Bhattacharyya A.K. Connor W.E. Lin D.S. McMurry M.M. Shulman R.S. Sluggish sitosterol turnover and hepatic failure to excrete sitosterol into bile cause expansion of body pool of sitosterol in patients with sitosterolemia and xanthomatosis.Arterioscler. Thromb. 1991; 11: 1287-1294Crossref PubMed Google Scholar, 13Yu L. Hammer R.E. Hawkins J.L. von Bergmann K. Lutjohann D. Cohen J.C. Hobbs H.H. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion.Proc. Natl. Acad. Sci. USA. 2002; 99: 16237-16242Crossref PubMed Scopus (603) Google Scholar, L. Hawkins J.L. Hammer R.E. Berge K.E. J.D. Cohen J.C. Hobbs H.H. of ABCG5 and ABCG8 biliary cholesterol secretion and of dietary 2002; PubMed Scopus (603) Google Scholar). that genetic variation in ABCG8 was associated with LDLC after statin therapy, is with these due to the that higher cholesterol synthesis be to cause a greater reduction in LDLC with statin therapy. a previous study that the plasma in carriers of the D19H variant was significantly lower than that of while the difference in plasma cholesterol levels to statistical K.E. von Bergmann K. Lutjohann D. Guerra R. Grundy S.M. Hobbs H.H. Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.J. Lipid Res. 2002; 43: 486-494Abstract Full Text Full Text PDF PubMed Google Scholar). In the study H. T. S. as of recurrent coronary events in of Scandinavian simvastatin 1998; PubMed Scopus Google Scholar), an plasma was associated with a response to simvastatin therapy a of treatment the responsible for was uncertain. may a for the five polymorphisms examined, the D19H variant was significantly associated with statin that the D19H variant or as variant, to have at 19 in ABCG8 is from plant to and its substitution to results in the of In the in ABCG5, is also In it is to that the D19H variant may in which as or ATP and the results of in the present study were with those of a previous K.E. von Bergmann K. Lutjohann D. Guerra R. Grundy S.M. Hobbs H.H. Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.J. Lipid Res. 2002; 43: 486-494Abstract Full Text Full Text PDF PubMed Google Scholar). statistical was due to of we to a specific ABCG5/8 that was significantly associated with the response to atorvastatin therapy than D19H variant could at least in part, by the that a of individuals any that two or previously that subjects with the genotype LDLC reductions after atorvastatin treatment than those with the in men (17Pedro-Botet J. Schaefer E.J. Bakker-Arkema R.G. Black D.M. Stain E.M. Corella D. Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Atherosclerosis. 2001; 158: 183-193Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar). In the present study, subjects also carried the D19H variant LDLC reductions ± and a lower posttreatment level of LDLC ± with subjects also were D19H ± ± that the D19H variant may for the of the in of LDLC In in patients with hypercholesterolemia, the ABCG8 D19H variant is significantly and associated with greater LDLC not with total cholesterol to atorvastatin therapy. was in by from and by and was also by the The and of for of ATP binding cassette transporter G8 apolipoprotein B body mass index total cholesterol LDL cholesterol cholesterol triglyceride

References

24